Autoantibodies against GLEA2 and PHF3 in glioblastoma: Tumor‐associated autoantibodies correlated with prolonged survival

Using serological identification of recombinantly expressed tumor antigens (SEREX), we identified several autoantibodies against glioma‐expressed antigens including GLEA1, GLEA2 and PHD‐finger protein3 (PHF3). Analysing sera of 62 glioblastoma patients, we found an antibody response against GLEA1 in...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2005-11, Vol.117 (3), p.456-459
Main Authors: Pallasch, Christian Philipp, Struss, Anne‐Katrin, Munnia, Angela, König, Jochem, Steudel, Wolf‐Ingo, Fischer, Ulrike, Meese, Eckart
Format: Article
Language:English
Subjects:
Antigens, Neoplasm - immunology
Autoantibodies
Biological and medical sciences
Biomarkers, Tumor - immunology
Brain Neoplasms - immunology
Brain Neoplasms - radiotherapy
Brain Neoplasms - surgery
Female
GLEA2
glioblastoma
Glioblastoma - immunology
Glioblastoma - mortality
Glioblastoma - radiotherapy
Glioblastoma - surgery
Humans
Male
Medical sciences
Middle Aged
Neurology
PHF3
prognosis
SEREX
Survival Analysis
Time Factors
Transcription Factors - immunology
Treatment Outcome
Tumors
Tumors of the nervous system. Phacomatoses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Using serological identification of recombinantly expressed tumor antigens (SEREX), we identified several autoantibodies against glioma‐expressed antigens including GLEA1, GLEA2 and PHD‐finger protein3 (PHF3). Analysing sera of 62 glioblastoma patients, we found an antibody response against GLEA1 in 15 sera (24.2%), against GLEA2 in 30 sera (48.4%) and against PHF3 in 35 sera (56.5%). Relating patient survival to the occurrence of autoantibodies against either GLEA1, GLEA2 or PHF3, we found a significant prolonged survival for glioblastoma patients positive for autoantibodies against GLEA2 (p = 0.0115) and PHF3 (p = 0.0031), respectively. The median survival of patients with GLEA2 antibodies was increased to 17.4 months and for patients with PHF3 antibodies to 14.7 months, as compared to 7.2 months for patients without GLEA2 or PHF3 antibodies. There was no significant correlation between patient survival and GLEA1‐autoantibodies (p = 0.1611). Herein we present autoantibodies that are: (i) most frequent in glioblastoma patients; (ii) specific for glioblastoma‐associated antigens; and (iii) significantly correlated with prolonged survival in patients with glioblastoma. © 2005 Wiley‐Liss, Inc.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.20929